Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ENZYMATICA Aktie jetzt für 0€ handeln | |||||
07.05. | Bulletin from the annual general meeting of Enzymatica AB (publ) on May 7, 2025 | 1 | Cision News | ||
05.05. | ENZYMATICA AB: Enzymatica gears up for global expansion after a strong first quarter | 3 | Cision News | ||
29.04. | Enzymatica AB: Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion | 205 | PR Newswire | LUND, Sweden, April 29, 2025 /PRNewswire/ --
First quarter
Net sales amounted to SEK 12.3 million (9.4).Operating result amounted to SEK -18.0 million (-18.4).Earnings per share... ► Artikel lesen | |
02.04. | Notice of Annual General Meeting 2025 in Enzymatica AB (publ) | 3 | Cision News | ||
11.03. | ENZYMATICA AB: Enzymatica's results published in The Journal of Physiology | 3 | Cision News | ||
06.03. | ENZYMATICA AB: Replay Link to Digital Press Briefing - March 5, 2025 | 3 | Cision News | ||
28.02. | Enzymatica AB: Invitation to Press Briefing - 5 March 2025 | 308 | PR Newswire | STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing... ► Artikel lesen | |
28.02. | Enzymatica AB: New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms | 344 | PR Newswire | STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- Today, results from two independent studies on the medical device ColdZyme were published in the peer-reviewed scientific journal The Journal of Physiology.... ► Artikel lesen | |
25.02. | ENZYMATICA AB: Enzymatica boosts Q4 revenue but sees room for stronger partner sales | 6 | Cision News | ||
18.02. | Enzymatica AB: Year-end report 2024: Strong performance in core markets - preparing for international growth | 225 | PR Newswire | LUND, Sweden, Feb. 18, 2025 /PRNewswire/ --
Fourth quarter
January-December
• Net sales reached SEK 17.2 million (15.8).
• The operating result totaled SEK -13.7... ► Artikel lesen | |
14.01. | ENZYMATICA AB: Enzymatica recruits experienced marketing director | 1 | Cision News | ||
09.01. | ENZYMATICA AB: Enzymatica focuses on growth with new recruitment - Anna Söderlund joins as Senior Director Marketing & Sales | 1 | Cision News | ||
07.11.24 | Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets | 354 | PR Newswire | LUND, Sweden, Nov. 7, 2024 /PRNewswire/ --
Third quarter
January-September
Net sales reached SEK 12.6 (13.3) million. The operating result totaled... ► Artikel lesen | |
22.08.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.08.2024 | 487 | Xetra Newsboard | Das Instrument EBZ BMG2109G1033 CHINA GAS HLDGS HD-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 22.08.2024 und ex Kapitalmassnahme am 23.08.2024 The instrument EBZ BMG2109G1033 CHINA GAS HLDGS... ► Artikel lesen | |
06.08.24 | Bulletin from the extraordinary general meeting of Enzymatica AB (publ) on 6 August 2024 | 371 | PR Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
LUND, Sweden, Aug. 6... ► Artikel lesen | |
18.07.24 | Enzymatica AB: Interim report Q2/2024: Enzymatica builds momentum for expansion | 552 | PR Newswire | LUND, Sweden, July 18, 2024 /PRNewswire/ --
Second quarter
January-June
Net sales reached SEK 6.4 (8.8) million. The operating... ► Artikel lesen | |
18.07.24 | Enzymatica AB: Enzymatica's Board of Directors updates the financial targets | 719 | PR Newswire | LUND, Sweden, July 18, 2024 /PRNewswire/ -- The Board of Directors of Enzymatica AB (publ) has decided to update the company's financial goals. The background is that the company will likely... ► Artikel lesen | |
18.07.24 | Notice of Extraordinary General Meeting in Enzymatica AB (publ) | 559 | PR Newswire | LUND, Sweden, July 18, 2024 /PRNewswire/ -- The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the Extraordinary General Meeting ("EGM")... ► Artikel lesen | |
18.07.24 | Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of approximately SEK 130 million | 151 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,435 | +0,02 % | Bayer, Vidac Pharma, Evotec - schnappen Sie sich den 866 Milliarden Onkologie Jackpot | Die Onkologie erlebt eine beispiellose Revolution. Mit prognostizierten 866 Mrd. USD Marktvolumen bis 2034 und 11 % Jahreswachstum treiben KI-gestützte Diagnosen, personalisierte Gentherapien und Präzisionsmedizin... ► Artikel lesen | |
NOVO NORDISK | 65,55 | +2,49 % | Unterbewertete Healthcare Titel - BioNxt Solutions, Evotec, Novo Nordisk | Wie der Einkaufsmanager-Index in der Euro-Zone zeigt, erholt sich die Stimmung in der Industrie von Südeuropa langsam. Schlusslicht bleibt dabei die Zuversicht der Geschäftsführer der größten deutschen... ► Artikel lesen | |
PFIZER | 20,510 | +0,15 % | Investor Woche: Nintendo launcht Switch 2, Tesla nach Musk-Trump-Drama im Sinkflug, EZB senkt Zinsen, Konjunkturdaten durchwachsen, Pfizer baut Stellen ab | Donald Trump und Elon Musk dominieren die Schlagzeilen: diese Woche durch das dramatisch vorgetragene Ende ihrer Männerfreundschaft. Dass Friedrich Merz im Oval Office war und die EZB die Zinsen senkte... ► Artikel lesen | |
GILEAD SCIENCES | 98,80 | +0,13 % | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
SANOFI | 89,11 | +0,01 % | Milliarden-Übernahme: Sanofi kauft sich mit 9,1 Milliarden US-Dollar in US-Biotech-Markt ein! | © Foto: Martin Joppen / SanofiDer französische Pharmariese Sanofi kündigt milliardenschweren Übernahme von Blueprint Medicines an. Die Ankündigung lässt die Aktie in die Höhe steigen!Der französische... ► Artikel lesen | |
GSK | 18,050 | -0,03 % | BERENBERG stuft GSK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat GSK nach gutem Lauf bei unverändertem Kursziel von 1600 Pence von "Buy" auf "Hold" abgestuft. Die Kursentwicklung des Pharmakonzerns sei in... ► Artikel lesen | |
ABBVIE | 166,40 | -0,12 % | AbbVie continues gains for seven straight sessions | ||
CANOPY GROWTH | 1,498 | +0,67 % | Canopy Growth has price target chopped at Roth | ||
STADA ARZNEIMITTEL | - | - | MIDDAY BRIEFING - Unternehmen und Märkte: HELLOFRESH, STADA, BRITISH AMERICAN TOBACCO, JULIUS BÄR, TOYOTA, TSMC | DJ MIDDAY BRIEFING - Unternehmen und Märkte
Der Markt-Überblick am Mittag, zusammengestellt von Dow Jones Newswires:
+++++ FEIERTAGSHINWEIS +++++
DIENSTAG: In Seoul findet wegen des Feiertages... ► Artikel lesen | |
ASTRAZENECA | 127,95 | +0,63 % | Buy or Goodbye?: Rheinmetall, LVMH, Nike und Astrazeneca - Die Analystenstimmen des Tages | © Foto: Marcus Brandt/dpaRheinmetall, LVMH, Nike und Astrazeneca: So bewerten Top-Analysten die Aktien. Ein Überblick.JPMorgan stuft Rheinmetall auf "Overweight" Die US-Bank JPMorgan hat die Einstufung... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 395,50 | +0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with... ► Artikel lesen | |
INNOCAN PHARMA | 0,111 | +2,31 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT clarifies disclosure about Premium Products buy | ||
CRONOS GROUP | 1,728 | -0,80 % | Cronos Group Inc.: Cronos Group Reports 2025 First Quarter Results | Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in... ► Artikel lesen |